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Abstract
Lysosomal membrane permeabilization is an essential step in TRAIL-induced apoptosis of liver cancer cell lines. TRAIL-
induced lysosomal membrane permeabilization is mediated by the multifunctional sorting protein PACS-2 and repressed by
the E3 ligases cIAP-1 and cIAP-2. Despite the opposing roles for PACS-2 and cIAPs in TRAIL-induced apoptosis, an interaction
between these proteins has yet to be examined. Herein, we report that cIAP-1 and cIAP-2 confer TRAIL resistance to
hepatobiliary cancer cell lines by reducing PACS-2 levels. Under basal conditions, PACS-2 underwent K48-linked poly-
ubiquitination, resulting in PACS-2 proteasomal degradation. Biochemical assays showed cIAP-1 and cIAP-2 interacted with
PACS-2 in vitro and co-immunoprecipitation studies demonstrated that the two cIAPs bound PACS-2 in vivo. More
importantly, both cIAP-1 and cIAP-2 directly mediated PACS-2 ubiquitination in a cell-free assay. Single c-Iap-1 or c-Iap-2
gene knock-outs in mouse hepatocytes did not lead to PACS-2 accumulation. However, deletion of both cIAP-1 and cIAP-2
reduced PACS-2 ubiquitination, which increased PACS-2 levels and sensitized HuH-7 cells to TRAIL-induced lysosomal
membrane permeabilization and apoptosis. Correspondingly, deletion of cIAPs sensitized wild-type, but not PACS-2-
deficient hepatocarcinoma cells or Pacs-22/2 mouse hepatocytes to TRAIL-induced apoptosis. Together, these data suggest
cIAPs constitutively downregulate PACS-2 by polyubiquitination and proteasomal degradation, thereby restraining TRAIL-
induced killing of liver cancer cells.
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Introduction
The inhibitor of apoptosis proteins (IAPs) are evolutionarily
conserved and implicated in a variety of cellular processes,
including repressing apoptosis in response to both extrinsic (death
receptors-mediated) and intrinsic (cell stress-mediated) signaling
pathways [1,2]. IAP family members share structural homology in
at least one baculovirus IAP repeat (BIR) domain, a stretch of,70
amino acids essential for protein-protein interactions. The
mammalian IAPs, cellular IAP protein 1 and 2 (cIAP-1 and
cIAP-2) and X chromosome-linked IAP (XIAP), contain three BIR
domains in their amino-terminal regions. In addition, these IAPs
bear a carboxyl-terminal RING (really interesting new gene)
domain that confers E3 ubiquitin ligase activity, and a ubiquitin-
associated (UBA) domain that enables binding of ubiquitin
moieties [3]. Despite early observations that all three IAPs can
directly bind caspases in vitro, only XIAP is actually a potent
inhibitor of caspase activity in vivo [4,5]. On the contrary, cIAP-1
and -2 exert their pro-survival effect mainly by means of their E3
ubiquitin ligase activity. They ubiquitinate specific substrates,
either targeting the proteins for proteasomal degradation by
catalyzing K48-linked polyubiquitination or modulating signaling
pathways by catalyzing K63-linked polyubiquitination [3].
IAP proteins are frequently overexpressed in human malignan-
cies and contribute to chemoresistance and poor prognosis [6].
These observations sparked the development of pharmacological
inhibitors of IAPs for potential use in cancer therapy. Small
molecules that mimic the IAP-binding motif of second mitochon-
drial activator of caspases (SMAC, also known as DIABLO), the
endogenous IAP antagonist [7,8], named SMAC mimetics, have
recently been developed and are being tested in human clinical
cancer trials. SMAC mimetics bind to the BIR2 and BIR3
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domains of IAPs and inhibit IAPs via two distinct mechanisms:
they can prevent binding of XIAP to active caspases [9] and they
can induce autoubiquitination and rapid proteasomal degradation
of cIAPs [9,10,11]. Pre-clinical studies have demonstrated the
ability of different SMAC mimetics to either exert single agent
cytotoxicity or sensitize tumor cells to pro-apoptotic stimuli
[6,12,13,14]. We recently reported that depletion of cIAP-1 by a
SMAC mimetic or by genetic knock-down overcomes the
resistance of hepatobiliary cancer cells to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) cytotoxicity, and that
cIAP-1 degradation is required for efficient TRAIL-induced
apoptosis [15]. In these cells, TRAIL treatment induces lysosomal
membrane permeabilization (LMP) followed by release of
cathepsin B and other lysosomal enzymes into the cytosol, which
is a crucial step in potentiating mitochondrial dysfunction [16,17].
Released cathepsin B appears to play a pivotal role in this
apoptotic pathway, as cathepsin B-deficient mice are resistant to
TRAIL-mediated liver injury [18]. We have also demonstrated
that TRAIL-induced LMP is, in part, mediated by the Bcl-2
proteins Bim and Bax [17]. TRAIL stimulates JNK-mediated
phosphorylation of Bim, which promotes the formation of a
lysosomal signaling complex (named PIXosome) with Bax and
phosphofurin acidic cluster sorting protein 2 (PACS-2) [19], a
member of the PACS family of multifunctional sorting proteins
regulating membrane traffic within secretory pathways and
interorganellar communication [20]. This complex triggers LMP
and promotes apoptosis, in accordance with a previous observa-
tion that PACS-2 is essential for TRAIL-induced hepatocyte
apoptosis in a model of viral hepatitis [21].
The present study aimed to investigate whether cIAPs may
prevent TRAIL-induced apoptosis by inhibiting the formation of
the PIXosome. We provide evidence that, in hepatobiliary cancer
cells, PACS-2 levels are regulated by cIAP-mediated polyubiqui-
tination and consequent proteasomal degradation. Depletion of
cIAP-1 and cIAP-2 results in PACS-2 accumulation, facilitating
LMP during TRAIL-induced cell death. This study identifies
PACS-2 as a key substrate for cIAPs and provides new insight into
the mechanisms underlying the antiapoptotic effect of IAP proteins
in TRAIL cytotoxic signaling.
Experimental Procedures
Reagents
Human recombinant TRAIL (375-TEC) was from R&D
Systems (Minneapolis, MN). The proteasome inhibitor MG132
was from Calbiochem (La Jolla, CA). The SMAC mimetic JP1584
was from Joyant Pharmaceuticals (Dallas, TX). All other reagents
were from Sigma-Aldrich (St. Louis, MO), unless otherwise
specified.
Antibodies
Rabbit polyclonal anti-PACS-2 (Ab193) was generated as
previously described [22]. Mouse monoclonal anti-S-peptide was
a generous gift from Dr. S. Kaufmann (Mayo Clinic, Rochester,
MN). The other primary antibodies for immunoblot analysis were
obtained from the following companies: rabbit polyclonal anti-
SAPK-JNK (9252) and rabbit polyclonal anti-phospho SAPK-
JNK (Thr183/Tyr185; 9251) from Cell Signaling (Beverly, MA);
goat polyclonal anti-cIAP-1 (AF8181) from R&D Systems; rabbit
monoclonal anti-cIAP-2 (clone E40; ab32059) from AbCam
(Cambridge, MA); rat monoclonal anti-HA tag (clone 3F10; 1-
867-423) from Roche Applied Science (Indianapolis, IN); rabbit
monoclonal anti-TRAF2 (5525-1) from Epitomics (Burlingame,
CA); mouse monoclonal anti-lysosomal associated membrane
protein 1 (LAMP1) from BD Pharmingen (San Diego, CA); goat
polyclonal anti-actin (sc-1615), mouse monoclonal anti-ubiquitin
(clone P4D1; sc-8017), rabbit polyclonal anti-GST (sc-459), mouse
monoclonal anti-His-probe (sc-8036); rabbit polyclonal anti-
cathepsin B (sc-13985), goat polyclonal anti-cathepsin D (sc-
6486) and goat polyclonal anti-cathepsin L (sc-6498) from Santa
Cruz Biochemicals (Santa Cruz, CA); rabbit monoclonal anti-
ubiquitin Lys63-specific (clone Apu3; 05-1308) and anti-ubiquitin
Lys48-specific (clone Apu2; 05-1307) from Millipore (Billerica,
MA). All primary antibodies were used at a concentration of 1 mg/
ml, except actin and total ubiquitin (0.25 mg/ml), and His-probe,
GST and cIAP-1 (0.5 mg/ml).
Cell Lines and Primary Mouse Hepatocytes
Hepatocellular carcinoma cell line HuH-7 [23] and derived
clones (HA-PACS-2-HuH-7, S-PACS-2-HuH-7, shPACS-2-HuH-
7) [19], cholangiocarcinoma cell lines KMCH-1 and Mz-ChA-1
(both a kind gift from Dr. Nicholas LaRusso, Mayo Clinic, and
obtained from Dr. M. Kojiro, Kurume University School of
Medicine, Kurume, Japan and Dr. A. Knuth, Mainz University,
Mainz, Germany, respectively) [24,25], MEFs and freshly isolated
primary mouse hepatocytes were all maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 mg/ml streptomycin and 100 units/ml
penicillin. TRAF2 knockout (Traf22/2 KO) MEFs, cIAP-1/cIAP-
2 double knockout (cIap-1/cIap-22/2 DKO) MEFs and respective
matching-background wild-type MEFs were a generous gift from
Dr. J. Silke (La Trobe University, Victoria, Australia) and were
generated as previously described [26]. Primary mouse hepato-
cytes were isolated from C57BL/6 wild-type mice (The Jackson
Laboratory, Bar Harbor, ME) or mice genetically deficient in
cIAP-1 (cIap-12/2) [27] or cIAP-2 (cIap-22/2) [28], both obtained
from Dr. J. Ashwell (NIH, Bethesda, MD), or PACS-2 (Pacs-22/2)
[21]. Mouse hepatocytes were isolated by collagenase perfusion,
purified by Percoll (Sigma) gradient centrifugation, and plated as
primary cultures.
Plasmids and Transient Transfection
The plasmids encoding N-terminally HA-tagged human PACS-
2 (pcDNA3.1-HA-PACS-2) have been previously described [21].
The plasmid encoding N-terminally S-peptide/streptavidin-bind-
ing peptide-double tagged PACS-2 (pSPN+SBP-PACS-2) was
constructed by inserting PCR-amplified DNA containing nucle-
otides 176–2845 of the human PACS-2 open reading frame
(NCBI Reference Sequence: NM_015197) into the BamHI and
EcoRI sites of pSPN+SBP (a kind gift of Dr. S. Kaufmann, Mayo
Clinic) [29]. The insert was amplified with Platinum Taq DNA
polymerase high fidelity (Invitrogen, Carlsbad, CA) using
pcDNA3.1-HA-PACS-2 as template and the following primers:
Fw: 59- AAT GGA TCC TAT GGC CGA GCG AGG C -39; Rv:
59- AAT GAA TTC TAG AAG GTG GCC TT -39, which
generated new BamHI and EcoRI sites. pEBB-HA-cIAP1H588A
(RING mutant) was generated as previously described [15]. The
plasmids were prepared for transfection using a plasmid midiprep
kit (Bio-Rad, Hercules, CA, USA), and were subjected to
automated sequencing to verify the presence of the described
mutations and the absence of additional unwanted mutations.
Cells growing in antibiotic-free DMEM+10% FBS were trans-
fected using FuGENE HD transfection reagent (Roche Applied
Science) with HD/DNA ratio 5:2, following the manufacturer’s
instructions. Cells were analyzed 48 hours after transfection.
PACS-2 Regulation by cIAPs
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Generation of Stable Transfectants
HuH-7 cells stably expressing HA-PACS-2 or shRNA against
PACS-2 were generated as previously described [19]. To obtain
clones stably expressing S-peptide/SBP-double tagged PACS-2,
HuH-7 cells were transfected with 1 mg/ml pSPN/SBP-PACS-2
using Lipofectamine 2000 (Invitrogen) in OptiMEM I (Gibco-
Invitrogen, Carlsbad, CA). Forty-eight hours after transfection,
fresh DMEM containing 1 mg/ml neomycin was added. Surviving
clones were selected and individually cultured. Expression of S-
peptide/SBP-double tagged PACS-2 in the clones was assessed by
immunoblot analysis for S-peptide
Immunoprecipitation and Pull-Down Assays
Cells were treated with MG132 (5 mM) for 4 hours, then
washed in ice-cold PBS and solubilized in lysis buffer (50 mM
HEPES [pH 7.2], 120 mM NaCl, 1 mM EDTA, 0.1% NP-40,
10% (w/v) glycerol, protease inhibitor cocktail) for 30 min on ice.
When samples were analyzed for ubiquitinated PACS-2, MG132
(20 mM) and N-ethylmalemide (NEM, 10 mM) were also added to
the lysis buffer. After centrifugation at 13,0006g for 15 min, the
supernatants were recovered and the protein concentration was
determined using the Bradford reagent (Sigma-Aldrich). In pull-
down experiments, aliquots containing 1–1.5 mg of protein were
incubated with EZview Red anti-HA affinity gel (Sigma-Aldrich)
or S protein agarose (Novagen/EMD Millipore) overnight at 4uC
under rotary agitation. In immunoprecipitation experiments,
aliquots containing 1.5 mg of protein were incubated with 10 mg
of anti-ubiquitin Lys63-specific or anti-ubiquitin Lys48-specific
antibodies, or 5 mg of anti-cIAP-2 antisera for 2 hours at 4uC, then
incubated overnight with protein A agarose beads (Millipore) at
4uC under rotary agitation. Pelleted proteins were solubilized in
SDS sample buffer, boiled for 5 min, clarified by centrifugation,
and subjected to SDS-PAGE and immunoblot analysis.
Immunoblot analysis
Whole-cell lysates were obtained as previously described [30].
Protein concentration was determined using the Bradford reagent
(Sigma-Aldrich). Aliquots containing 50 mg of protein were
resolved by SDS-PAGE, transferred to nitrocellulose membrane
and blotted with primary antibodies overnight at 4uC. HRP-
conjugated secondary antibodies (Santa Cruz) were incubated at a
dilution of 1:3000 for 1 hour at room temperature. Bound
antibodies were visualized using enhanced chemiluminescence
reagents (ECL; GE Healthcare, Buckinghamshire, UK).
Generation of recombinant proteins
Plasmids expressing GST, GST-PACS-2FBR38–202 correspond-
ing to residues 38–202 (cargo/adaptor-binding region-FBR) [31]
and pET15b-FBR2 plasmid expressing His6-PACS-2FBR38–217
[22] were induced in BL21-A1 E. coli (Invitrogen) with 1 mM
isopropyl-b-D-thiogalactoside (Calbiochem, Gibbstown, NJ) and
0.2% L-arabinose (Sigma Aldrich) for 4 hours at 37uC. Bacterial
pellets were resuspended in PBS (pH 7.4) containing 1 mM PMSF
and 1 mM DTT, subjected to sonication, and incubated on ice for
30 min in the presence of 1% Triton X-100. Soluble material was
recovered by centrifugation at 13,0006g for 20 min at 4uC and
subsequently purified using GSTrap FF affinity columns (GE
Healthcare, Piscataway, NJ) or HisPur Ni-NTA Spin Columns
(Thermo Scientific/Pierce Biotechnology, Rockford, IL) following
the manufacturer’s instructions.
In Vitro Binding Assay
Aliquots of recombinant GST-PACS-2 FBR38–202 or GST
(,200 ng) were incubated for 30 min at 4uC in 20 ml of assay
buffer (20 mM Tris, pH 7.9; 150 mM NaCl; 0.1 mM EDTA,
0.1% NP-40) with recombinant cIAP-1 and/or cIAP-2 (500 ng;
R&D Systems), in the presence or absence of recombinant His-
TRAF2 (500 ng; Sigma Aldrich). At the end of the incubation, the
volume of each sample was brought to 400 ml with assay buffer
and GST-containing proteins were affinity-purified by adding
40 ml of GST-agarose beads (BioWorld, Dublin, OH) for 30 min
at 4uC. The agarose beads were recovered after centrifugation at
3,2006g for 2 min, washed once in assay buffer and four times in
PBS, and the bound complexes were eluted by adding equal
volumes of electrophoresis sample buffer, boiling for 5 min and
centrifuging at 8,0006g for 1 min to pellet the beads. The
supernatants containing the eluted proteins were analyzed by
immunoblot.
In Vitro Ubiquitination Assay
Aliquots of recombinant His-PACS-2FBR38–217 (,1 mg) were
incubated for 1 hour at 37uC in 50 ml of assay buffer (30 mM
HEPES, pH 7.5; 2 mM DTT; 10 mM ZnCl2; 5 mM MgCl2;
2 mM ATP) containing 250 ng of recombinant cIAP-1 or cIAP-2
(E3), 0.5 mg E1 (Ube1), and 1 mg E2 (UbcH5a), in the presence of
10 mg ubiquitin (all reagents from Boston Biochem, Cambridge,
MA). At the end of the incubation, after addition of electrophoresis
sample buffer, the samples were boiled for 5 min, centrifuged at
10,0006g for 1 min and analyzed by immunoblot.
PACS-2 Translocation to Lysosomes and Assessment of
Lysosomal Membrane Permeabilization (LMP)
Lysosomal fractions from cultured cells were obtained using a
commercially available Lysosome Isolation Kit (Sigma-Aldrich)
and analyzed by immunoblot.
LMP was assessed by immunoblot analysis for lysosomal
enzymes (cathepsin B, cathepsin D and cathepsin L) in the
cytosolic fractions, as well as by cathepsin B immunofluorescence
in fixed cells. Cytosolic fractions were obtained by a selective
digitonin permeabilization technique validated by Garrison and
coworkers [32] with slight modifications. Briefly, cells were washed
and collected in PBS containing a protease inhibitor cocktail
(Roche), centrifuged at 1,2006g for 5 min and incubated on ice for
5 min in permeabilization buffer (20 mM HEPES, pH 7.2,
100 mM KCl, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
250 mM sucrose, protease inhibitor cocktail and 0.01% digitonin).
This concentration of digitonin was chosen after validation studies
demonstrated its ability to selectively permeabilize the plasma
membrane, but not the lysosomal membrane (data not shown).
Samples were subsequently centrifuged at 15,0006g at 4uC for
10 min, and the supernatants were collected and analyzed by
immunoblot.
Cathepsin B immunofluorescence was performed as previously
described [19], using a mouse monoclonal anti-cathepsin B
antibody (clone CA10, #1M27L, Calbiochem/EMD Millipore)
at dilution 1:500. Cells were mounted using the ProLong Gold
antifade reagent with DAPI (Molecular Probes), imaged by
confocal microscopy (Zeiss LSM 510, Carl Zeiss Micro-Imaging
Inc., Thornwood, NJ) with lem = 488 nm and lex = 507 nm, and
scored for their punctate versus diffuse fluorescence.
PACS-2 Regulation by cIAPs
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Quantification of Apoptosis
Apoptosis was quantified by fluorescence microscopy after
staining with 49,6-diamidino-2-phenylindole dihydrochloride
(DAPI, Sigma) as previously described [15].
Animal Studies
All animal studies were performed in accord with and approved
by the Mayo Clinic Institutional Animal Care and Use Commit-
tee. Three to four month-old C57BL/6 wild-type and Pacs-22/2
mice were given the mouse DR5-specific monoclonal antibody
MD5-1 (300 mg/mouse) [33] intraperitoneally once on day 1 and
once on day 4 of the study. Gender- and age-matched, untreated
wild-type and Pacs-22/2 mice were used as controls. The mice
were euthanized 18 days after the first injection and livers and
blood were removed for analysis. Serum transaminase (alanine
aminotransferase, ALT; aspartate aminotransferase, AST) activity
was measured using standardized and automated procedures of
the diagnostic laboratory at the Mayo Clinic. Tissue samples were
cryopreserved in Tissue Tek OTC compound (Takeda, Deerfield,
IL) immediately after removal.
TUNEL Assay
Liver apoptotic cells were quantitated by the terminal deox-
ynucleotidyl transferase-mediated dUTP nick-end labeling (TU-
NEL) assay. Cryopreserved liver tissue sections were cut at 5 mm
on a cryomicrotome (Leica, Buffalo Grove, IL) and air-dried.
TUNEL assay was performed using the In Situ Cell Death
Detection Kit with Fluorescein (Roche Diagnostics, Indianapolis,
IN) following the manufacturer’s protocol. TUNEL-positive cells
were counted using an inverted laser scanning confocal micro-
scope (Zeiss LSM 780) with lem = 480 nm and lex = 525 nm. A
total of five high-power fields (HPF) were analyzed for each
animal.
Statistical analysis
All data represent at least three independent experiments and
are expressed as means 6 standard errors (SE), unless otherwise
indicated. Differences between groups were analized using one-
way analysis of variance (ANOVA) for multiple groups; individual
group means were compared with Student’s unpaired t test. P
values,0.05 were considered statistically significant.
Results
Posttranslational regulation of PACS-2 by proteasomal
degradation
The determination that JNK phosphorylation of Bim Ser69 is
required for PIXosome assembly and LMP, together with the
ability of cIAPs to regulate death receptor-induced JNK activation
and apoptosis in liver cancer cells [15] [19] [34], led us to ask if
cIAP inhibitors can block TRAIL-induced LMP by preventing
Bim phosphorylation. Therefore, we examined TRAIL-mediated
JNK activation in hepatocellular carcinoma HuH-7 cells in the
presence or absence of the SMAC mimetic JP1584, which induces
rapid degradation of cIAP-1 and cIAP-2. We found that JP1584
had no measurable effect on TRAIL-induced JNK activation,
suggesting SMAC mimetics block TRAIL action downstream of
Bim phosphorylation in this model (Fig. 1A).
We then tested the possibility that cIAPs regulate PACS-2.
Initially, we asked whether PACS-2 may be ubiquitinated.
Accordingly, HuH-7 cells stably expressing HA-tagged PACS-2
[19] were lysed and PACS-2 ubiquitination status was examined
after HA immunoprecipitation and immunoblot analysis with an
ubiquitin specific antibody. High molecular weight species
visualized as a ‘‘smear’’ on the blot suggested PACS-2 was
constitutively polyubiquitinated in these cells (Fig. 1B). To
determine the ubiquitin linkage of the polyubiquitin chains on
PACS-2, HA-PACS-2 cell lysates were subjected to immunopre-
cipition using anti-ubiquitin Lys48-specific or Lys63-specific
antibodies, then subsequently immunoblotted using anti-HA
antiserum. PACS-2 polyubiquitination was detected only in the
pull-down with anti-ubiquitin Lys48-specific but not Lys63-specific
antibody (Fig. 1C), suggesting the polyubiquitin chains on PACS-2
were linked primarily through lysine 48 of ubiquitin. As Lys48-
linked polyubiquitination typically targets a protein for degrada-
tion via the proteasomal pathway, we postulated that inhibition of
the proteasome would lead to cellular accumulation of PACS-2.
Indeed, HuH-7 cells treated with MG132 displayed a time-
dependent increase of both endogenous PACS-2 and stably
expressed, exogenous S-peptide/SBP-double tagged PACS-2
(Fig. 1D). These results were not cell line specific, as virtually
identical observations were made in the cholangiocarcinoma cell
lines KMCH and Mz-ChA-1 (Fig. 1D). Thus, these findings
indicate that PACS-2 cellular levels are in part regulated by K48-
linked polyubiquitination and proteasomal degradation in hepa-
tobiliary cancer cells.
cIAPs ubiquitinate PACS-2 in vivo and in vitro, and
promote its degradation
Given the role of degradative ubiquitination in PACS-2
regulation, we next sought to ascertain if cIAPs could act as E3
ubiquitin ligases for PACS-2. HA-PACS-2 HuH-7 cells were
incubated in the presence or absence of JP1584 for 1 hour,
subjected to HA immunoprecipitation and analyzed by immuno-
blot for PACS-2 ubiquitination (Fig. 2A). HA-PACS-2 polyubi-
quitination was markedly reduced in cells treated with the SMAC
mimetic, suggesting that IAPs are critical E3 ligases responsible for
PACS-2 ubiquitination (Fig. 2A). Treatment with JP1584 also
resulted in time-dependent accumulation of both endogenous
PACS-2 and S-peptide/SBP-double tagged PACS-2 in all cell lines
(Fig. 2B, upper and lower panel, respectively), confirming that
IAPs modulate PACS-2 degradation. To ascertain if PACS-2
ubiquitination was carried out specifically by cIAP-1 or cIAP-2, we
examined PACS-2 protein levels in total liver lysates from cIap12/
2 or cIap22/2 mice. Surprisingly, no accumulation of PACS-2 was
detected in either sample compared to the wild-type liver lysate,
suggesting depletion of both cIAP-1 and cIAP-2 may be necessary
to reduce PACS-2 degradation (Fig. 2C). Given the unavailability
of liver tissue from cIap12/2cIap22/2 DKO mice as these mice die
during embryonic development, we assessed the levels of PACS-2
in cIap12/2cIap22/2 DKO MEFs and compared them with wild-
type MEFs. Endogenous PACS-2 was indeed more abundant in
unstimulated cIap12/2cIap22/2 DKO MEFs compared to wild-
type MEFs (Fig. 2D). Moreover, ubiquitination of exogenous
PACS-2 was reduced in the cIap12/2cIap22/2 DKO MEFs
(Fig. 2D). Therefore, it appears that cIAP-1 and cIAP-2 act
coordinately and redundantly to ubiquitinate PACS-2. TRAF2
binds to cIAP-1 and cIAP-2, recruiting them to different signaling
complexes [35], and has been shown to stabilize cIAP-1 [36]. In
order to verify whether the cellular levels of PACS-2 were affected
by the absence of TRAF2, PACS-2 was analyzed in wild-type and
Traf22/2 MEFs. PACS-2 levels were comparable in both cell
lines, suggesting TRAF2 is dispensable for cIAP regulation of
PACS-2 (Fig. 2E). Finally, we tested the ability of cIAP-1 and
cIAP-2 to directly ubiquitinate PACS-2 in a cell-free ubiquitina-
tion assay. Given the difficulties to obtain recombinant full-length
PACS-2 from a bacterial system due to extensive bacterial
PACS-2 Regulation by cIAPs
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degradation, we generated recombinant His-PACS-2FBR38–217
which contains residues 38–217 corresponding to the cargo/
adaptor-binding region-FBR of PACS-2. Purified His-PACS-
2FBR was incubated with recombinant cIAP-1 or cIAP-2 in the
presence of recombinant E1 and E2 (UbcH5a) enzymes, in a
reaction buffer containing ubiquitin and ATP. Incubation of His-
PACS-2FBR with cIAP-1 or cIAP-2 resulted in PACS-2FBR
polyubiquitination (Fig. 2F), indicating that PACS-2 is a direct
substrate for both cIAP-1 and cIAP-2.
cIAPs bind to PACS-2 in vivo and in vitro
To confirm that IAPs and PACS-2 physically interact, cells were
co-transfected with S-peptide/SBP-double tagged PACS-2 and
HA-tagged cIAP-1 RING mutant, in which His588 had been
mutated to Ala, abrogating the E3 ubiquitin ligase activity of cIAP-
1. The use of the RING mutant was necessary in order to achieve
higher expression of the exogenous HA-cIAP-1, as the wild-type
protein undergoes rapid auto-ubiquitination and proteasomal
degradation when overexpressed [36]. Pull-down of HA-cIAP-1
displayed an interaction between cIAP-1 and PACS-2 (Fig. 3A).
Moreover, immunoprecipitation of endogenous cIAP-2 also
demonstrated association of PACS-2 with cIAP-2 (Fig. 3A). To
determine whether cIAPs bind directly to PACS-2 or may require
another co-factor (i.e., TRAF2), we assessed the ability of PACS-2
to co-precipitate with cIAP-1 or cIAP-2 in a cell-free system using
purified components. Purified recombinant GST-PACS-2FBR
(Fig. 3B, left panel) or GST (used as control to assess nonspecific
binding; Fig. 3B, right panel) were incubated with cIAP-1 or cIAP-
2, in the presence or absence of recombinant His-TRAF2; GST-
containing proteins were subsequently immunoprecipitated using
GST-agarose beads and the resulting samples were subjected to
immunoblot analysis. Despite the finding that TRAF2 does not
seem to be required for cIAP-mediated downregulation of PACS-2
(Fig. 2E), cIAP-1, cIAP-2 and TRAF2 all bound GST-PACS-2-
FBR in vitro, alone or in combination (Fig. 3B); likely, TRAF2 is
associating with cIAP-1 and -2 in this cell-free system as has been
previously demonstrated [37]. The binding of cIAP-1, cIAP-2 or
TRAF2 did not occur in the GST region of GST-PACS-2-FBR, as
GST alone did not associate with any of the proteins (Fig. 3B, right
panel).
PACS-2 accumulation facilitates TRAIL-induced LMP
Because PACS-2 trafficking to lysosomes promotes TRAIL-
mediated LMP [19], we speculated that cellular accumulation of
PACS-2 may increase sensitivity to TRAIL-induced LMP. To test
this possibility, lysosomal fractions were prepared from HuH-7
cells treated with TRAIL in the presence or absence of JP1584,
and analyzed by immunoblot for PACS-2. PACS-2 was translo-
cated to lysosomes more rapidly and efficiently when cells were
incubated with TRAIL plus JP1584 compared to TRAIL alone
(Fig. 4A). Notably, the increased translocation of PACS-2 to the
lysosomes in the presence of the SMAC mimetic was coupled with
an accelerated onset of LMP, as demonstrated by release of
lysosomal cathepsin B, D and L into the cytosol (Fig. 4A). The
Figure 1. PACS-2 levels are regulated by K48-linked polyubiquitination and proteasomal degradation. (A) HuH-7 cells were treated
with TRAIL (20 ng/ml) in the presence or absence of the SMAC mimetic JP1584 (500 nM) for up to 4 hours. Total cell lysates were analyzed by
immunoblot with antisera against total and phospho-JNK (T183/Y185), cIAP-1, cIAP-2 and actin (loading control). (B) HuH-7 cells stably over-
expressing HA-PACS-2 or wild-type HuH-7 cells were lysed and subjected to HA pull-down using HA agarose beads. The samples were analyzed by
immunoblot with antisera against total ubiquitin. (C) HuH-7 cells over-expressing HA-PACS-2 were lysed and subjected to immunoprecipitation using
antibodies against Lys48-linked or Lys63-linked poly-ubiquitin, then analyzed by immunoblot for HA. Total cell lysates show equal expression of HA-
PACS-2 in the samples. (D) HuH-7 cells (left panel) or HuH-7, KMCH and Mz-ChA-1 cells transiently transfected with S-peptide/SBP-double tagged
PACS-2 (right panel) were treated with MG132 (10 mM) for the indicated times. PACS-2 cellular levels were analyzed by immunoblot in total cell
lysates.
doi:10.1371/journal.pone.0092124.g001
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membrane fractionation studies were corroborated by confocal
microscopy. Parallel plates of Huh-7 WT and shPACS-2 cells were
treated with TRAIL or JP1584 alone or in combination and the
subcellular distribution of cathepsin B was monitored by cell
imaging. In control cells, cathepsin B displayed a punctate staining
pattern characteristic of lysosomes. Addition of JP1584 alone did
not change cathepsin B localization. However, following treatment
with TRAIL, the cathepsin B staining pattern became diffuse,
consistent with lysosome permeabilization and release of cathepsin
B into the cytoplasm (Fig. 4B and C). Addition of JP1584 to
TRAIL further increased the amount of diffuse cytosolic staining,
suggesting the two compounds cooperate to induce LMP. By
contrast, HuH-7 cells with targeted shRNA knockdown of PACS-
2 [19] were resistant to LMP mediated by TRAIL and JP1584,
confirming that PACS-2 plays a key role in the induction of LMP
(Fig. 4B and C).
PACS-2 Deficiency Protects from TRAIL-induced
Hepatocyte Apoptosis and Liver Injury and Prevents
Sensitization by the SMAC Mimetic
To test whether the absence of PACS-2 also confers resistance
to TRAIL-induced hepatocyte apoptosis, we first treated WT and
shPACS-2 HuH-7 cells with TRAIL in the presence or absence of
JP1584. Consistent with the observation that PACS-2 is necessary
for LMP, shPACS-2 cells were also resistant to TRAIL-induced
apoptosis and were not sensitized by the SMAC mimetic (Fig. 5A).
Conversely, cells over-expressing PACS-2 displayed enhanced
sensitivity to TRAIL-induced apoptosis (Fig. 5B). Next, we
conducted a side-by-side analysis of primary hepatocytes isolated
from WT, cIap-12/2, cIap-22/2, or Pacs-22/2 mice. Cultured
primary hepatocytes do not undergo apoptosis following treatment
with several forms of recombinant soluble TRAIL or TRAIL-
receptor agonists [38]. Our previous studies indicated the same
soluble TRAIL used in this study was unable to induce significant
apoptosis in primary rat hepatocytes [39]. In agreement with these
Figure 2. PACS-2 is ubiquitinated by cIAPs in vivo and in vitro. (A) HA-PACS-2-overexpressing HuH-7 cells were incubated with or without
JP1584 (500 nM) for 1 hr, followed by HA pull-down and immunoblot analysis with antisera against total ubiquitin or HA. Total lysates prior HA pull-
down were immunoblotted for cIAP-1. Images were cut and combined from the same film to remove adjacent unrelated lanes. (B) HuH-7 cells ( upper
panel) and HuH-7, KMCH and Mz-ChA-1 cells transiently transfected with S-peptide/SBP-double tagged PACS-2 ( lower panel) were treated with
JP1584 for the indicated times. PACS-2, cIAP-1 and cIAP-2 levels were analyzed by immunoblot. The asterisk (*) indicates a non-specific band. (C) Total
liver lysates from wild-type, cIap12/2 or cIap22/2 mice and (D) cIap12/2cIap22/2 DKO (c1/2 DKO) MEFs and matching background wild-type MEFs
were analyzed by immunoblot for PACS-2 expression (left panel). cIap12/2cIap22/2 DKO MEFs and wild-type MEFs were transiently transfected with
S-peptide/SBP-double tagged PACS-2, subjected to S-peptide pull-down and analyzed by immunoblot with antisera against total ubiquitin or S-
peptide (right panel). (E) Traf22/2 (T2 KO) and matching background wild-type MEFs were analyzed by immunoblot for PACS-2 expression. Actin was
used as loading control. (F) An in vitro ubiquitination assay was performed by incubating His-PACS-2FBR38–202 with recombinant E1, UbcH5a (E2) and
cIAP-1 or cIAP-2 (E3), in buffer containing wild-type ubiquitin and ATP, for 1 hour at 37uC. PACS-2FBR38–202 ubiquitination was detected by
immunoblot analysis using antisera against the His-tag.
doi:10.1371/journal.pone.0092124.g002
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observations, WT mouse hepatocytes displayed no apoptosis in
response to TRAIL or JP1584 alone. However, WT hepatocytes
were sensitized to apoptosis when the two molecules were added in
combination (Fig. 5C). By contrast, primary hepatocytes from
Pacs-22/2 mice were resistant to TRAIL and JP1584 added
singularly or together. Primary hepatocytes from cIap12/2 or
cIap22/2 mice were also resistant to TRAIL-induced apoptosis,
demonstrating that the absence of either protein is not sufficient to
sensitize the cells to TRAIL. However, JP1584 sensitized cIap-22/
2 hepatocytes to TRAIL, whereas the cIap-12/2 hepatocytes
retained their resistance (Fig. 5C). Finally, we verified whether
mice genetically deficient in PACS-2 were protected from TRAIL-
induced hepatocyte apoptosis and liver damage in vivo. In an
experimental model employing a mouse DR5-specific antibody
(MD5-1) capable of inducing liver damage [40], Pacs-22/2 mice
displayed significantly less apoptosis and liver damage compared
to C57BL/6 wild-type mice as assessed by TUNEL assay and
serum transaminase levels, respectively (Fig. 6A and B). Collec-
tively, these data indicate that PACS-2 is required for TRAIL-
induced LMP and cell death, and demonstrate that accumulation
of PACS-2 in the absence of cIAPs facilitates its translocation to
lysosomes and sensitizes cells to TRAIL killing.
Discussion
The results of this study identify a novel mechanism by which
cIAPs mediate resistance to TRAIL-induced apoptosis in liver
cancer cells, namely, by regulating the formation of the PACS-2,
Bim, Bax-containing signaling complex PIXosome on the
lysosomes. The principal findings indicate that (i) PACS-2 is
constitutively polyubiquitinated and degraded via the proteasome
pathway in liver cells; (ii) cIAPs bind to and directly ubiquitinate
PACS-2; (iii) pharmacological depletion (by SMAC mimetics) or
genetic deletion of both cIAP-1 and cIAP-2 impairs PACS-2
ubiquitination and results in its intracellular accumulation; and (iv)
PACS-2 accumulation facilitates its translocation to the lysosomes
following TRAIL treatment, promoting TRAIL-induced LMP
Figure 3. cIAP-1 and cIAP-2 bind to PACS-2 in vivo and in vitro. (A) HuH-7 cells untransfected or transiently transfected with S-peptide/SBP-
double tagged PACS-2 6 HA-cIAP-1H588A expression plasmids were subjected to HA (cIAP-1) pull-down or cIAP-2 immunoprecipitation. Affinity-
purified proteins and total cell lysates (input) were analyzed by immunoblot for S-peptide (PACS-2), cIAP-1 and cIAP-2. Images were cut and
combined from the same film to remove adjacent unrelated lanes. The asterisk (*) indicates a non-specific band. (B) An in vitro binding assay was
performed by incubating recombinant GST or GST-PACS-2FBR38–202 with recombinant cIAP-1 or cIAP-2, in the presence or absence of recombinant
human His-TRAF2, for 30 min at 4uC. GST was subsequently pulled-down and the precipitates were analyzed by immunoblot with the indicated
antibodies.
doi:10.1371/journal.pone.0092124.g003
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and apoptosis. Each of these observations is discussed in greater
detail below.
We have reported that PACS-2 is required for TRAIL-induced
apoptosis and that inhibition of IAPs, in particular cIAP-1,
sensitizes liver cancer cells to TRAIL-induced apoptosis [15,19].
Whether these molecules interact with and/or regulate each other,
however, was not investigated in those studies. cIAPs possess E3
ubiquitin ligase activity and are known to modulate ubiquitin-
dependent signaling events triggered by death receptor activation.
Herein, we provide data suggesting PACS-2 is ubiquitinated via
Lys48-linked poly-ubiquitin chains in untreated hepatobiliary
cancer cells, which results in its proteasomal degradation.
Consequently, PACS-2 cellular levels are repressed in these cells.
Our findings suggest cIAPs function as E3 ligases for PACS-2
ubiquitination, as cellular depletion of cIAP-1 and cIAP-2 by a
SMAC mimetic reduced PACS-2 ubiquitination and resulted in
PACS-2 accumulation. Our previous studies pointed to a
prominent role for cIAP-1 in TRAIL-resistance in liver cancer
cells [15]; therefore, we anticipated that cIAP-1 would be mainly
responsible for PACS-2 ubiquitination. Unexpectedly, both cIAP-
1 and cIAP-2 ubiquitinate PACS-2 in a redundant manner, as the
absence of either protein alone does not affect PACS-2
ubiquitination or protein stability. Only the simultaneous deple-
tion of cIAP-1 and cIAP-2, as observed following the use of a
SMAC mimetic or in cIAP-12/2cIAP-22/2 DKO MEFs, results
in inefficient PACS-2 ubiquitination and accumulation within the
cell. cIAP depletion has also been reported to indirectly enhance
cFLIPL degradation, thereby facilitating caspase 8 activation [41],
a process which would also promote TRAIL pro-apoptotic
signaling. Thus, it is likely that cIAPs exert their anti-apoptotic
effect on multiple signaling pathways.
In agreement with the observation that PACS-2 is a substrate
for cIAPs, immunoprecipitation studies identified direct binding
between PACS-2 and cIAP-1 and cIAP-2 both in vivo and in cell-
free systems. TRAF2 has been shown to stabilize cIAP-1 [36], and
is required for cIAP-mediated degradation of NIK, as well as for
SMAC mimetic-induced cIAP autoubiquitination and degradation
[42,43]. Interestingly, although TRAF2 co-precipitates with
PACS-2 in cell-free systems, in the presence or absence of cIAP-
1 and/or cIAP-2, it seems to be dispensable for cIAP ubiquitina-
tion and downregulation of PACS-2. Moreover, although TRAF2
was readily co-precipitated with cIAP-1, we were unable to
identify TRAF2 in complex with PACS-2 in cell lysates (data not
shown). These observations suggest that cIAP-1 and cIAP-2 might
independently associate with PACS-2 and TRAF2 in different
intracellular pools, and that TRAF2 is not recruited to the PACS-
2:cIAP-1:cIAP-2 complex in vivo.
PACS-2 interacts with Bim and Bax to induce lysosomal
membrane permeabilization, a step required for efficient TRAIL-
mediated apoptosis in liver cells [17,19,44]. In the current study,
simultaneous depletion of cIAP-1 and cIAP-2 results in PACS-2
accumulation and enhances PACS-2 translocation to the lyso-
somes following TRAIL-treatment. Functionally, this was accom-
panied by more efficient LMP, as demonstrated by the release of
Figure 4. PACS-2 accumulation facilitates its translocation to the lysosomes. (A) HuH-7 cells were treated with TRAIL (10 ng/ml) 6 JP1584
(500 nM). At the indicated times, lysosomal and cytosolic fractions were obtained and subjected to immunoblot analysis. LAMP1, an integral
lysosomal membrane protein, and actin were used as loading control in the lysosomal and cytosolic fractions, respectively. (B) Wild-type and shPACS-
2 HuH-7 cells were treated with TRAIL 6 JP1584 for 3 hours and intracellular localization of cathepsin B was detected by immunofluorescence and
imaged by confocal microscopy. (C) Quantification of the cells with permeabilized lysosomes was performed by scoring for punctate or diffuse
appearance of cathepsin B and is expressed as percent of total number of cells per field. *p,0.02.
doi:10.1371/journal.pone.0092124.g004
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lysosomal cathepsins into the cytosol, and increased cell death.
Further evidence that PACS-2 acts at the level of the lysosomes
comes from the observation that PACS-2 deficient HuH-7 cells
display both reduced LMP and sensitivity to TRAIL-induced
apoptosis. More importantly, TRAIL sensitivity was not restored
by a SMAC mimetic in PACS-2 deficient cells, confirming that
IAPs act upstream of PACS-2-mediated LMP. Primary mouse
hepatocytes are resistant to apoptosis induced by the recombinant
TRAIL used in this study. Indeed, no apoptosis was detected in
wild-type mouse hepatocytes after TRAIL-treatment; however,
these cells were sensitized to apoptosis by the use of the SMAC
mimetic, suggesting that IAPs may be involved in the intrinsic
resistance of primary hepatocytes to TRAIL. On the contrary,
inhibition of IAPs by the SMAC mimetic did not restore sensitivity
to TRAIL-induced apoptosis in Pacs-22/2 mouse hepatocytes, in
agreement with what observed in HuH-7 cells. TRAIL-induced
apoptosis in cIap12/2 hepatocytes was not enhanced by the
presence of the SMAC mimetic, but it was restored in cIap22/2
hepatocytes. This is consistent with the recent observation that in
the absence of cIAP-1, cIAP-2 is unable to auto-ubiquitinate in
response to SMAC mimetics, therefore it does not undergo
proteasomal degradation and accumulates overtime [43]. The
persistent high levels of cIAP-2 in cIap12/2 mouse hepatocytes
likely account for their failure to undergo TRAIL-induced
apoptosis even in the presence of a SMAC mimetic.
In conclusion, our results have identified PACS-2 as a substrate
for the E3 ubiquitin ligase activity of cIAPs and unveiled a novel
mechanism through which cIAPs modulate TRAIL-induced
apoptosis in hepatobiliary cells. Loss of cIAPs reduces PACS-2
ubiquitination and results in PACS-2 accumulation, facilitating its
translocation to the lysosomes and promoting TRAIL-induced cell
death. These findings highlight the crucial role for cIAPs in
regulating TRAIL-resistance, and demonstrate that cIAPs and
PACS-2 antagonistically regulate TRAIL-induced LMP and
apoptosis.
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